Daiichi vitamin production
This article was originally published in The Tan Sheet
Daiichi Fine Chemical has decided to stop production of vitamin B6 (pyridoxine HCl) at its Takaoka City, Japan facility effective July 31. Firm cites "poor global market conditions" as primary reason for exiting business. Following July closing date, Daiichi Pharmaceutical subsidiary will utilize facility to produce pharmaceutical intermediates and shift its focus to vitamin B5 (pantothenic acid) production. Firm manufactures 10 different forms of pantothenic acid for use in human nutrition, personal care and pharmaceutical products...
You may also be interested in...
Dispatches from a world turned upside down include FDA expressing confidence in Chinese manufacturers – to make their GDUFA payments; projections of drug shortages for ventilator patients; and the launch of new hydroxychloroquine studies.
A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.
Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.